Journal of ISSN: 2377-4312 JDVAR

Dairy, Veterinary & Animal Research
Case Report
Volume 3 Issue 3

New therapeutic protocol for canine babesiosis: a case report

Nandini MK,1 Poonam Vishwakarma,2 Ansar Kamran C3
1The Companion Animal Clinic, India
2Biosafety Support Unit, India
3Department of Teaching Veterinary Clinical Complex, Hasan Veterinary College, India
Received: May 17, 2016 | Published: June 06, 2016
Correspondence: Poonam Vishwakarma, Scientist, Biosafety Support Unit, Regional Centre for Biotechnology, Government of India, New Delhi, India, Tel 011 2465 4007, Email
Citation: Nandini MK, Vishwakarma P, Kamran CA. New therapeutic protocol for canine babesiosis: a case report. J Dairy Vet Anim Res. 2016;3(3):112‒113. DOI: 10.15406/jdvar.2016.03.00082


Canine babesiosis is typically characterized by hemolyticanemia, thrombocytopenia, fever, and splenomegaly. A male Labrador aged three years eight months was presented to the veterinary clinic with a history of brownish urination, anorexia and lethargy since one week. Clinical examination revealed high temperature (105.70F), pale mucous membrane and splenomegaly. Haematology revealed anaemia and thrombocytopenia (Hb- 7.7g/dl; Platelet count- 86,000/µl). B. Gibsoni (+++) was evidenced in blood smear. Treatment was initiated with a combination therapy of Clindamycin @ 25mg/kg PO q 12h, Metronidazole @ 15mg/kg PO q 12h and Doxycycline @ 5mg/kg PO q 12h for 10days. There was no adverse reactions and the dog showed clinical and haematological improvement from 4th day of treatment onwards and recovered uneventfully by the end of therapeutic protocol.

Keywords: B. gibsoni, canine, clindamycin, metronidazole, doxycycline, combination therapy, haematology, biochemistry


Hb, haemoglobin; TLC, total leucocyte count: SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic-pyruvic transaminase; ALP, alkaline phosphatase; @, at sign; SC, subcutaneous; IM, intramuscular


Babesiosis is an important disease of domestic dogs and has been attributed to infection with either Babesia canis or B. Gibsoni, based on parasite size and the geographic location in which the infection was acquired. It is diagnostically important to determine the species that causes canine babesiosis, since the virulence, prognosis, and response to anti babesial drugs may be different for each organism.1 Babesia gibsoni was first recognized in India in 1910.2 There are at least three distinct isolates of B. Gibsoni that are morphologically identical: one from Asia, one from California, and a third from Europe. The Asian isolate is the original organism found in India and is considered Babesia gibsoni sensustricto.3

Case presentation

A male Labrador aged three years eight months was presented with a history of brownish urination, anorexia and lethargy since one week. Clinical examination revealed high temperature (105.70 F), pale mucous membrane and spleenomegaly. Blood was collected and subjected to routine hematology and biochemistry. Peripheral smear study revealed presence of B. gibsoni (+++) in the RBCs. Based on clinical signs, hematological and biochemical report case was suspected for Babesiosis and blood smear confirmed it as B. gibsoni infection.

The animal was treated with Clindamycin @ 25 mg/kg PO q 12h, Metronidazole @ 15 mg/kg PO q 12h and Doxycycline @ 5 mg/kg PO q 12h for 10 days and was advised for follow up after 3 days. On fourth day of treatment temperature was normal (101.80 F), parasitemia was reduced to less than 10%, there was clinical and hematological improvement. Owner was further advised to come after four days for blood test (Table 1).


Day 1

Day 4

Day 7





Platelet count (lakhs/ µl)




TLC (103/µl)




Neutrophils (%)




Eosinophils (%)




Lymphocytes (%)




Monocytes (%)




Creatinine (mg/dl)
















Total bilirubin (mg/dl)




Direct bilirubin (mg/dl)




Total protein (g/dl)




Albumin (g/dl)




Globulin (g/dl)




Albumin : Globulin ratio




Table 1 Haematological and Biochemical findings in affected dog


Conventional therapy for canine Babesiosis includes 2 doses of Inj. Imidocarbdipropionate @ 5mg/kg SC or IM 2weeks apart. It reduces morbidity and mortality but ineffective for clearance of B. Gibsoni. Other drug used to treat Babesiosis is single injection of Diminazeneaceturate @ 3.5mg/kg SC or IM, but this is potentially dangerous and shows a propensity to develop severe cerebral toxicity with classic cerebellar sulci haemorrhages. Moreover, B. Gibsoni are very difficult to clear with such conventional therapy and dogs usually become chronic carriers or present with recurrent episodes of acute babesiosis.4

The first treatment that has been shown to be effective against B. Gibsoni is a combination of atovaquone and azithromycin.5 Unfortunately Atovaquone is not available in India and it’s expensive for import. Moreover Possible Emergence of Drug-Resistant Variants of B. Gibsoni in clinical cases treated with Atovaquone and Azithromycin has also been reported.6

In the present case, combination of Clindamycin, Metronidazole and Doxycycline gradually reduced parasitemia levels and Clindamycin treatment reduced the clinical symptoms characteristic of Babesia infection, including anemia, anorexia, and listlessness also subsided. The effectiveness of clindamycin for treatment of B. Gibsoni infection has also been reported by several workers.7,8 But it’s been suggested that clindamycin might not eliminate parasites rapidly from the peripheral blood but damages it which might stimulate humoral and cellular immunity against Babesia infection and results in improvement in clinical condition.9 So, a Combination therapy of clindamycin (CLDM), metronidazole (MNZ), and doxycycline (DOXY) as an efficacious alternative treatment strategy for B. Gibsoni infection with no adverse effects has been suggested.10

Thus, present clinical case concluded that a combination therapy of Clindamycin @ 25mg/kg, Metronidazole @ 15mg/kg and Doxycycline @ 5mg/kg for 10days is effective against B. Gibsoni with no adverse reactions and the dog showed uneventful recovery.



Conflict of interest

Author declares that there is no conflict of interest.


  1. Birkenheuer AJ, Levy MG, Breitschwerdt EB. Development and Evaluation of a Seminested PCR for Detection and Differentiation of Babesia gibsoni (Asian Genotype) and B. canis DNA in Canine Blood Samples. J Clin Microbiol. 2003;41(9):4172‒4177.
  2. Patton WS. Preliminary report on a new piroplasm (Piroplasmagibsoni sp. nov.) found in the blood of the hounds of the Madras Hunt and subsequently discovered in the blood of the jackal Canisaureus. Bull Soc Pathol Exot. 1910;3:274‒280.
  3. Trapp SM, Messick JB, Vidotto O,et al. Babesia gibsoni genotype Asia in dogs from Brazil. Vet Parasitol. 2006;141(1‒2):177‒180.
  4. Schoeman JP. Canine babesiosis. Onderstepoort J Vet Res. 2009;76(1):59‒66.
  5. Birkenheuer AJ, Levy MG, Breitschwerdt EB. Efficacy of combined atovaquone and azithromycin for therapy of chronic Babesiagibsoni (Asian genotype) infections in dogs. J Vet Intern Med. 2004;18(4):494‒498.
  6. Sakuma M, Setoguchi A, Endo Y. Possible Emergence of Drug-Resistant Variants of Babesiagibsoni in Clinical Cases Treated with Atovaquone and Azithromycin. J Vet Intern Med. 2009;23(3):493‒498.
  7. Wulansari R, Wijaya A, Ano H, et al. Clindamycin in the Treatment of Babesia gibsoni Infections in Dogs. J Am Anim Hosp Assoc. 2003;39(6):558‒562
  8. Stegeman JR, Birkenheuer AJ, Kruger JM, et al. Transfusion-associated Babesia gibsoni infection in a dog. American Journal of Veterinary Research. 2003;222(7):959‒963.
  9. Wulansari R, Wijaya A, Ano H, et al. Lymphocyte subset and specific IgG antibody levels in Clindamycin treated and untreated dogs experimentally infected with Babesia gibsoni. J Vet Med Sci. 2003;65(5):579‒584.
  10. Suzuki K, Wakabayashi H, Takahashi M, et al. A possible treatment strategy and clinical factors to estimate the treatment response in Babesia gibsoniinfection. J Vet Med Sci. 2007;69(5):563‒568.
©2016 Nandini et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.
© 2014-2018 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy